<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553393</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-060</org_study_id>
    <nct_id>NCT04553393</nct_id>
  </id_info>
  <brief_title>Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden</brief_title>
  <official_title>Treatment of Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Plus Epigenetic Agents in Aggressive Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients With Huge Tumor Burden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, multi-cohorts, phase 1/2 study has the primary objective of comparing&#xD;
      decitabine-primed tandem CART 19/20 solo, with decitabine-primed tandem CART 19/20 plus&#xD;
      chidamide, decitabine-primed tandem CART 19/20 plus decitabine, and decitabine-primed tandem&#xD;
      CART 19/20 plus decitabine+chidamide in patients with aggressive B-NHL who were confirmed as&#xD;
      Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma with hugh tumor burden (Sum of the&#xD;
      Product of the perpendicular Diameters for multiple lesions, SPD ≥ 100cm^2 or the&#xD;
      largest-diameter of tumor ≥ 10 cm.).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">September 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 8, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events after intervention</measure>
    <time_frame>12 months</time_frame>
    <description>Safety Outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate Outcome Measure</measure>
    <time_frame>2 years</time_frame>
    <description>ORR assess by investigators per the 2014 Lugano classification rate of subjects achieved objective response in all evaluable subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention treatment-related adverse events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory research</measure>
    <time_frame>12 months</time_frame>
    <description>Track cart cells in PB after infusions by TCR, transcriptional, and epigenetic sequencing.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden</condition>
  <arm_group>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tandem dual Specificity targeting CD19 and CD20 decitabine-primed CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of chidamide and decitabine can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function, induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide will be added 1 month after responding to CART cells infusion</description>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide</arm_group_label>
    <other_name>cohort 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine will be added 1 month after responding to CART cells infusion</description>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine</arm_group_label>
    <other_name>cohort 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide and Decitabine</intervention_name>
    <description>Both chidamide and decitabine will be added 1 month after responding to CART cells infusion</description>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine</arm_group_label>
    <other_name>cohort 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decitabine-primed Tandem CAR19/20 engineered T cells</intervention_name>
    <description>Tandem CAR19/20 engineered T cells</description>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells</arm_group_label>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide</arm_group_label>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine</arm_group_label>
    <arm_group_label>Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine</arm_group_label>
    <other_name>cohort 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥16 and ≤ 65 years.&#xD;
&#xD;
          2. Sum of the Product of the perpendicular Diameters for multiple lesions, SPD ≥ 100cm^2&#xD;
             or the largest-diameter of tumor ≥ 10cm.&#xD;
&#xD;
          3. Histologically confirmed CD20+ and/or CD19+ aggressive B-cell non-Hodgkin lymphoma&#xD;
             (NHL), including the following types defined by the World Health Organization (WHO)&#xD;
             2016:&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma (DLBCL).&#xD;
&#xD;
               -  High grade B-cell lymphoma(HGBL).&#xD;
&#xD;
               -  Other aggressive B-cell lymphoma.&#xD;
&#xD;
          4. Refractory disease or relapse after treatment with ≥2 lines of chemotherapy, including&#xD;
             rituximab and anthracycline and either having failed autologous hematopoietic stem&#xD;
             cell transplantation (HSCT), being ineligible for autologous HSCT or not consenting to&#xD;
             autologous HSCT.&#xD;
&#xD;
             We defined chemotherapy-refractory disease as meeting one or more of the following&#xD;
             criteria:&#xD;
&#xD;
               -  No response to first-line therapy (primary refractory disease).&#xD;
&#xD;
               -  No response to second-line or later therapy.&#xD;
&#xD;
               -  Progressive disease (PD) as the best response to the most recent therapy regimen.&#xD;
&#xD;
               -  Stable disease (SD) as the best response after at least 2 cycles of the most&#xD;
                  recent line of therapy with an SD duration of no longer than 6 months from the&#xD;
                  last dose of therapy.&#xD;
&#xD;
             Failure following autologous HSCT was defined as follows:&#xD;
&#xD;
               -  PD or relapsed disease ≤12 months after autologous stem cell transplantation&#xD;
                  (ASCT) (requires biopsy-proven recurrence in relapsed subjects).&#xD;
&#xD;
               -  No response or relapse after salvage therapy is given post-ASCT.&#xD;
&#xD;
          5. PD or relapse ≥3 months after treatment with targeted CD19 therapy, including CD19 CAR&#xD;
             T cells or anti-CD19/anti-CD3.&#xD;
&#xD;
          6. Successful leukapheresis assessment and preculture of T cells.&#xD;
&#xD;
          7. Life expectancy &gt; 3 months.&#xD;
&#xD;
          8. Adequate organ function:&#xD;
&#xD;
               -  Creatinine &lt; 1.6 mg/dL (140 µmol/L) or creatinine clearance ≥60 mL/min.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &lt; 3× upper limit&#xD;
                  of the normal range.&#xD;
&#xD;
               -  Bilirubin &lt;2.0 mg/dL unless the subject had Gilbert's syndrome (&lt;3.0 mg/dL).&#xD;
&#xD;
               -  A minimum level of pulmonary reserve defined as ≤ grade 1 dyspnoea and pulse&#xD;
                  oxygenation &gt; 91% with room air.&#xD;
&#xD;
               -  Cardiac ejection fraction ≥50%, no evidence of pericardial effusion as determined&#xD;
                  by an echocardiogram (ECHO), and no clinically significant electrocardiogram&#xD;
                  (ECG) findings.&#xD;
&#xD;
          9. An adequate bone marrow reserve defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC)&gt;1,000/mm3.&#xD;
&#xD;
               -  Absolute lymphocyte count (ALC)≥300/mm3.&#xD;
&#xD;
               -  Platelet count ≥ 50,000/mm3.&#xD;
&#xD;
               -  Haemoglobin &gt; 7.0 mg/dL.&#xD;
&#xD;
         10. Measurable or assessable disease according to the &quot;IWG Response Criteria for Malignant&#xD;
             Lymphoma&quot; (Cheson 2014). Patients in complete remission (CR) with no evidence of&#xD;
             disease were not eligible.&#xD;
&#xD;
         11. Informed consent/assent requiring that all patients have the ability to understand and&#xD;
             the willingness to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with definite involvement of the gastrointestinal tract. Endoscopy should be&#xD;
             performed to confirm gastrointestinal involvement in suspected patients. However,&#xD;
             patients with central nervous system (CNS) involvement were cautiously enrolled in&#xD;
             this clinical study.&#xD;
&#xD;
          2. Detection of a clear HAMA effect in patients with prior CD19 CAR T cell treatment&#xD;
             failure or recurrence, or negative tumour puncture detection of CD19 and CD20.&#xD;
&#xD;
          3. Pregnant or lactating women.&#xD;
&#xD;
          4. Uncontrolled active bacterial or viral infection (active hepatitis B or hepatitis C&#xD;
             infection, HIV infection) or treponema pallidum infection.&#xD;
&#xD;
          5. Class III/IV cardiovascular disability according to the New York Heart Association&#xD;
             Classification and a cardiac ejection fraction ≥50%.&#xD;
&#xD;
          6. History of allo-HSCT.&#xD;
&#xD;
          7. Requirement for urgent therapy due to tumour mass effects such as respiratory&#xD;
             obstruction or blood vessel compression.&#xD;
&#xD;
          8. Current or expected need for systemic corticosteroid therapy.&#xD;
&#xD;
          9. Any organ failure.&#xD;
&#xD;
         10. Patients with a second tumour requiring therapy or intervention.&#xD;
&#xD;
         11. Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 2.&#xD;
&#xD;
         12. Subjects considered unlikely to complete all protocol-required study visits or&#xD;
             procedures, including follow-up visits, or comply with the study requirements for&#xD;
             participation according to the investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weidong Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weidong Han, M.D.</last_name>
    <phone>+861055499341</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han, M.D</last_name>
      <phone>+86-10-66937463</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
    <investigator>
      <last_name>Weidong Han, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yajing Zhang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhiqiang Wu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingming Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chuan Tong, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunmeng Wang, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dongdong Ti, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianshu Wei, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deyun Chen, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

